



Rational Vaccine Design against Malaria

Guest Editors:

Dr. Hirdesh Kumar

Dr. Peeyush Ranjan

Dr. Vinay Kumar

Dr. Sarita Puri Mishra

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editors

Dear Colleagues,

Malaria remains one of the most devastating and life-threatening diseases worldwide that causes more than half a million deaths annually. The currently available malaria vaccine, RTS,S/AS01, can prevent malaria in young African children noting a 30% reduction in deadly severe anemia. However, higher vaccine efficacy is much needed. Therefore, it is necessary to identify potential vaccine candidates to elicit more robust protective responses against malaria. In light of malaria parasites' available genomic, proteomic, and metabolomic information, it is the most promising time to switch from traditional empirical approaches to advanced, rational designs, and to identify potent malaria vaccine candidates.

We are pleased to invite you to submit your manuscript related to novel strategies for malaria vaccine design. We welcome original research articles describing novel malaria vaccine candidates based on (but not limited to) parasite-focused and reverse vaccinology, structural vaccinology, and/or immunoinformatics.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com